Reduced toxicity of protein/magnetic targeted drug delivery system for improved skin cancer treatment in mice model
Source abstract
Abstract
Abstract Skin cancer is one of the most common types of cancers. Although majority of skin cancers can be treated effectively if they are diagnosed at an early stage, delayed treatment for some types, such as melanoma, are life threatening. This current study evaluated the therapeutic effects of a recently developed targeted drug delivery system (DDS) to treat an experimental skin squamous cell carcinoma (SCC) in a mouse model. This DDS can release drugs into the body at a designated rate and location. The system consists of biodegradable polymer microspheres of encapsulated magnetic nanoparticles, human albumin, and 5-fluorouracil (5-FU). While the magnetic forces keep the nanocomposite spheres in the targeted cancer area, the protein promotes increased absorption of the DDS near cancer cells to release the therapeutic agent. While tumor sizes were significantly decreased and cancer tissue underwent dramatic necrosis, no remote organ and lymph node metastasis were observed. The tissue specimens collected from vital organs (lungs, liver, kidneys, and lymph nodes adjcent to the cancer sites) were histologically examined and did not showobvious damages and adverse tissue responses after the DDS injections. Overall, this study confirmed that this DDS is successful in treating cancer without toxic effects and may be a possible alternative to traditional therapies.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Skin Protection and Aging · Nanoparticle-Based Drug Delivery · Advancements in Transdermal Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (15)
Show source-provided references
1. Sun exposure, sun protection, and vitamin D10.1001/jama.294.12.1541 ↗
2. Skin cancer (nonmelanoma skin cancer). http://www.medicinenet.com/skin_cancer/article.htm (accessed 5 August 2010).
3. Perspectives on cancer therapy with radiolabeled monoclonal antibodies
4. Is anticancer drug development heading in the right direction?10.1158/0008-5472.CAN-08-3786 ↗
5. Albumin-based drug delivery as novel therapeutic approach for rheumatoid arthritis10.4049/jimmunol.170.9.4793 ↗
6. R. Asmatulu, A. Fakhari, H.L. Wamocha, H.Y. Chu, et al., Drug-carrying magnetic nanocomposite particles for potential drug delivery systems, J. Nanotechnol. (2009) 6 pages, Article ID 238536. doi: 10.1155/2009/238536.10.1155/2009/238536 ↗
7. Sustained releasing of methotrexate from injectable and thermosensitive chitosan-carbon nanotube hybrid hydrogels effectively controls tumor cell growth10.1021/acsomega.8b03212 ↗
8. Investigating MTX-loaded magnetic nanocomposite particles for treatment of rheumatoid arthritis10.1016/j.jmmm.2019.166171 ↗
9. Albumin-based micro-composite drug carriers with dual chemo-agents for targeted breast cancer treatment10.1177/0885328215569614 ↗
10. Skin cancer treatment by albumin/5-fu loaded magnetic nanocomposite spheres in a mouse model10.1016/j.jbiotec.2013.01.003 ↗
11. Cytotoxicity of release products from magnetic nanocomposites in targeted drug delivery10.1177/0885328211421989 ↗
12. Misak · 2011
13. Albumin-based nanocomposite spheres for advanced drug delivery systems10.1002/biot.201300150 ↗
14. Doctor on board? What is the optimal skill-mix in military pre-hospital care?
15. Sequential drug verification errors resulting in wrong drug administration during caesarean section10.1016/j.ijoa.2010.07.007 ↗